AbbVie (ABBV)

AI-powered earnings call analysis for AbbVie. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

20 episodes 5 languages

Latest Episode

Q3 2026 Earnings

6:52 • 10/31/2026

AbbVie (ABBV) - Q3 2026

0:00

6:52

Speed:

Q3 2026 Earnings

8:01 • 2026/10/31

AbbVie (ABBV) - Q3 2026

0:00

8:01

Speed:

Q3 2026 Earnings

8:06 • 31/10/2026

AbbVie (ABBV) - Q3 2026

0:00

8:06

Speed:

Q3 2026 Earnings

10:12 • 31/10/2026

AbbVie (ABBV) - Q3 2026

0:00

10:12

Speed:

Q3 2026 Earnings

9:02 • 31.10.2026

AbbVie (ABBV) - Q3 2026

0:00

9:02

Speed:

All Episodes

EN - English (4) CN - 中文 (4) FR - Français (4) ES - Español (4) DE - Deutsch (4)

Q3 2026 Earnings

6:52

AbbVie's Q3 revenues of $17.4B beat expectations with 10.5% operational growth; company raised FY guidance to $67.8B and increased dividend 5.2%.

Q2 2026 Earnings

6:08

AbbVie delivered strong Q2 with $17.0B revenue (+10.2%), adjusted EPS of $3.65, raising full-year guidance to $67.6B amid robust growth in immunology and neuroscience.

Q1 2026 Earnings

6:41

AbbVie delivered strong Q1 2026 results with $15.0B revenue (+12.4%) and $2.65 adjusted EPS, raising full-year guidance to $14.08-$14.28 on robust immunology and neuroscience momentum, while advancing transformational pipeline programs including Skyrizi combinations and obesity therapeutics.